Amgen Successfully Concludes First-Ever CIIE Debut, Advancing Health Innovation in China

ShanghaiNovember 10, 2022PR Newswire -- Today, the 5th China International Import Expo (CIIE) has officially come to an end. As a "new friend" of the CIIE, Amgen participated with the theme "Unite to Accelerate, Heal the Future Together," leveraging the significant "spillover effect" of the CIIE to introduce Repatha.^®And Prolia^®Two InnovationsTherapy, and the world's first KRAS-targeted treatment drug Lumakras^®The China Debut of Sotorasib^[1]During the CIIE, Amgen not only took the stage at the "New Products Launch Platform," but its multiple booth activities also attracted widespread attention from all sectors of society. Numerous media representatives, industry insiders, and visitors came to interact, fully demonstrating Amgen's influence as a global biotechnology leader.

"Amgen Chairman and CEO Bob Bradway said, 'As a global biotechnology leader, Amgen is honored to showcase our cutting-edge R&D capabilities and innovative medicines designed to address some of today’s most significant healthcare challenges at this year’s CIIE.'"

Introducing Cutting-Edge Global Products to Enhance the Accessibility of Innovative Medicines

Amgen's debut booth at the CIIE is located in Hall 7.2, A1-03 of the Medical Devices and Healthcare Products Exhibition Area. Centered around the theme "Unite and Accelerate · Heal the Future Together," it comprehensively showcases how Amgen has, over the past decade in China, focused on addressing significant yet unmet patient needs, expedited the introduction of cutting-edge global products into China, collaborated with all parties to promote healthy aging, and continuously improved the accessibility of innovative drugs.

Amgen Digs Deep into Local Needs, BringingTwo InnovationsTherapy -- Repatha in the Field of Cardiovascular Diseases^®And Prolia in the field of bone health^®, continuously meeting the needs of Chinese patients for chronic disease treatment. The event also featured an assessment for atherosclerotic cardiovascular disease (ASCVD) risk stratification and an osteoporosis risk self-test, which attracted many attendees to scan codes and participate, allowing them to learn about their cardiovascular and bone health status on-site.^[2]。

"Happy Bones Initiative": Protecting Women's Healthy "Pride"

In China, about one-third of women over the age of 50 suffer from osteoporosis. To raise more awareness about the importance of bone health, on November 7, Amgen, in collaboration with the China Women's Development Foundation, held a showcase event at its debut exhibition booth for the "Happy Bones Action – Female Bone Health Education Project." The event called on the public to pay attention to the timely management of osteoporosis and aimed to enhance women’s awareness of preventing the condition. Several leaders, guests, and bone expert representatives attended the event.

"Happy Bones Action - Women's Bone Health Education Project" Exhibition Site

For a long time, Amgen China has continuously focused on the field of bone health, committing to promote Prolia.^®Representing the introduction of globally leading innovative therapies into China, improving drug accessibility for postmenopausal osteoporosis patients, and actively collaborating with authoritative osteoporosis experts across the country to explore new approaches, concepts, and technologies in the standardized management of osteoporosis, thereby enhancing the quality of patient diagnosis and treatment, and jointly creating a new blueprint for women's bone health!

Amgen Vice President and General Manager for China, Carol Hui, stated at the exhibition: "Osteoporosis requires long-term management by patients, and improving the prevention and treatment system for osteoporosis necessitates the joint efforts of all sectors of society. As a global leader in bone health, Amgen hopes to unite with all parties, deepen cooperation, and accelerate benefits for more patients."

Lumakras^® China's First Exhibition: Bringing Breakthrough Targeted Therapies to Lung Cancer Patients

On the afternoon of November 8, Amgen introduced Lumakras, the world's first KRAS-targeted therapeutic drug, via the "CIIE New Products Hub" platform.^®(Sotorasib) Makes Its China Debut. For 40 years, the KRAS target has been one of the most formidable challenges in cancer research, and treating KRAS mutations was once considered "undruggable." However, Amgen has made significant progress with KRAS.^G12CThe development of the inhibitor sotorasib took less than three years, making it the fastest research progress project in its history, demonstrating Amgen's R&D strength in addressing the "undruggable" challenge.

Recently, on the list of the "Prix Galien Award," known as the "Nobel Prize of the pharmaceutical industry," Lumakras^®(Sotorasib) also won the 2022 "Best Drug Award." In February 2021, Lumakras^®(Sotorasib) has been designated as a "Breakthrough Therapy" by the Center for Drug Evaluation of the National Medical Products Administration.

Non-small cell lung cancer, as the most common type of lung cancer, accounts for approximately 80-85% of global lung cancer cases.^[3]The KRAS G12C mutation is the most common type of KRAS mutation in non-small cell lung cancer.^[4],[5]In Chinese patients with non-small cell lung cancer, this mutation is a biomarker of poor prognosis, and G12C-specific inhibitors are expected to improve their prognosis.^[6]。

Lumakras(R) Makes China Debut at "CIIE New Products Showcase"

Continue to Deepen Presence in China, Embark on a New Journey of Accelerated Growth in China

The Chinese market is of strategic importance to Amgen and serves as a significant engine for the growth of Amgen’s business in the Asia-Pacific region and globally. Through the China International Import Expo (CIIE), Amgen has fully experienced China's comprehensive, multi-level, and broad-based pattern of opening up. Amgen's Vice President and General Manager for China, Ada Hsu, stated, "We have deeply felt China's commitment to continuous openness, which further strengthens Amgen's dedication to cultivating the Chinese market. We will continue to fulfill Amgen's corporate mission of 'serving patients,' accelerate the process of bringing global innovative achievements to benefit Chinese patients, and are committed to working with all sectors of society to support 'Healthy China 2030.'"

Amgen hopes to leverage the "spillover effect" of the CIIE to transform exhibits into products, while also focusing on introducing global innovative therapies and building a product line that closely aligns with the needs of Chinese patients. Amgen will take this as a new starting point, adopting a more open posture to collaborate with all parties in constructing an ecosystem for chronic disease management, continuously seizing "Chinese opportunities," advancing together with China, and contributing to building a healthier future!

[1] Lumakras^®(Sotorasib) has not yet been officially approved for marketing in China.
[2] For reference and use by healthcare professionals only
[3] American Cancer Society. Available at https://www.cancer.org/cancer/lung-cancer/about/what-is.html#:~:text=About%2080%25%20to%2085%25%20of,(outlook)%20are%20often%20similar.
[4] Pakkala S, et al. JCI Insight. 2018;3:e120858. 
[5] Arbour KC, et al. Clin Cancer Res. 2018;24:334-340.
[6] Liu S, et al. Clinical characteristics and prognostic value of the KRAS G12C mutation in Chinese non-small cell lung cancer patients. Biomark Res 8, 22 (2020). https://doi.org/10.1186/s40364-020-00199-z.